03rd week of 2012 patent applcation highlights part 34 |
Patent application number | Title | Published |
20120014932 | Methods for treating disorders of amino acid metabolism - The invention is directed to methods for treating disorders of amino acid metabolism, in particular, phenylketonuria (PKU). Such methods utilize novel compositions including Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) alone or in combination with other agents or treatment modalities. | 2012-01-19 |
20120014933 | Method for Producing Platelets - The present invention relates to a method for producing platelets from mature megakaryocytes. More particularly, the invention relates to an ex vivo method for producing platelets, from mature megakaryocytes, said method comprising a step of subjecting a suspension of mature megakaryocytes to a flow having a minimal shear rate of 600 s | 2012-01-19 |
20120014934 | Enhanced Natural Colors - A natural color is concentrated to intensify color range and to provide useful amounts of one or more of anti-oxidant, nutritional, and anti-inflammatory compounds derived from one or more pigment sources. In a preferred embodiment, the pigment source is a fruit, a vegetable, a legume, a spice, algae, or a combination thereof. | 2012-01-19 |
20120014935 | RECOMBINANT HUMAN CLN2 PROTEIN AND METHODS OF ITS PRODUCTION AND USE - The present invention relates to a method for treating a patient having disorder characterized by a deficient amount of functional CLN2 protein in the affected cells, which comprises administering to the patient an amount of CLN2 protein effective to reduce or eliminate the symptoms caused by the deficiency in CLN2 protein. | 2012-01-19 |
20120014936 | METHODS AND COMPOSITIONS FOR CNS DELIVERY OF HEPARAN N-SULFATASE - The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A. | 2012-01-19 |
20120014937 | Human Beta-Adrenergic receptor kinase polypeptide and methods - Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP. | 2012-01-19 |
20120014938 | Angiogenic Tyrosyl t-RNA Synthetase Compositions and Methods - The present invention provides an isolated tyrosyl tRNA synthetase (TyrRS) polypeptide variant which comprises (a) a Rossmann fold region or a portion thereof, preferably including an α5 coil; and (b) an anticodon recognition domain or portion thereof, preferably including an α14 coil. Preferably, the α5 coil and the α14 coil have a greater spatial separation in the tertiary structure of the variant compared to the corresponding spatial separation in native human TyrRS. The variant preferably comprises an amino acid residue sequence identity of at least about 50% compared to the amino acid residue sequence of human TyrRS (SEQ ID NO: 3), includes at least one non-conservative amino acid residue substitution relative to the amino acid residue sequence of human TyrRS, and preferably presents an exposed ELR motif in the α5 coil on an external portion of the tertiary structure of the polypeptide. A preferred TyrRS protein variant comprises the amino acid residue sequence of SEQ ID NO: 4 or a portion thereof. The proteins and protein fragments of the invention are angiogenic and are useful for stimulating angiogenesis in mammalian tissues. | 2012-01-19 |
20120014939 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF HAEMORRHAGIC CONVERSION - The invention provides a method for predicting a hemorrhagic disorder in a patient consisting determining amine oxidase and, particularly, VAP-1 in a sample from said patient. The invention also provides pharmaceutical compositions comprising an inhibitor of amine oxidase and an antithrombotic agent as well as the use of an inhibitor of amine oxidase for treatment of hemorrhagic disorders. | 2012-01-19 |
20120014940 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF MALIGNANT AND NON-MALIGNANT GAMMOPATHIES - The invention relates, at least in part, to the identification of paratarg as a paraprotein target in various malignant and non-malignant gammopathies, which can be used in the diagnosis and treatment of either. | 2012-01-19 |
20120014941 | ANTI-BV8 ANTIBODIES AND USES THEREOF - The present invention concerns antibodies to Bv8 and the uses of same. | 2012-01-19 |
20120014942 | METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF MALIGNANT DISEASES - Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin. | 2012-01-19 |
20120014943 | Optimized Anti-CD30 Antibodies - An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody. | 2012-01-19 |
20120014944 | PREVENTION AND TREATMENT OF PAIN USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID - Methods for preventing or treating pain are provided. Such methods comprise administering to a subject (e.g., a human subject) an antibody or antibody fragment that binds LPA. The antibody may be a humanized monoclonal antibody. | 2012-01-19 |
20120014945 | Anti-Dengue Virus Antibodies - Provided herein are monoclonal antibodies specific to dengue virus as well as their antigen-binding fragments, and functional variants. Also disclosed are uses thereof for treating or diagnosing dengue virus infection. | 2012-01-19 |
20120014946 | PREVENTION AND TREATMENT OF PAIN USING MONOCLONAL ANTIBODIES AND ANTIBODY FRAGMENTS TO LYSOPHOSPHATIDIC ACID - Methods for preventing and treating pain are provided. These methods involve administering to a subject, including a human subject, an antibody or antibody fragment that binds LPA. Preferably, antibody is a humanized anti-LPA monoclonal antibody, or an antigen-binding fragment derived from such an antibody. | 2012-01-19 |
20120014947 | METHODS AND COMPOSITIONS TO REDUCE LIVER DAMAGE ASSOCIATED WITH CONDITIONS OR THERAPIES THAT AFFECT THE IMMUNE SYSTEM - One side-effect arising from the use of antibodies against TNF receptor family members as therapeutics can be liver damage which precludes the completion of clinical trial. A novel LT-dependent pathway is described that mediates liver cell injury in several disease models. | 2012-01-19 |
20120014948 | GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND USE THEREOF - The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which the genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor. | 2012-01-19 |
20120014949 | Serum Biomarkers For Early Detection Of Acute Cellular Rejection - The present invention provides an improved method of diagnosing a subject having received an organ transplant with Acute Cellular Rejection (ACR). The method comprises obtaining a biological sample from the subject, detecting an amount of at least one protein indicative of ACR in the sample, and comparing the amount of the protein in the sample to a control, wherein a difference between the amount of the protein in the sample relative to the control indicates the subject has or is developing ACR. The difference can be an increase or a decrease. In one version the biological sample comprises a serum sample, and the transplanted organ is selected from a heart, kidney, liver, bone marrow, pancreas, eye, lung or skin. Methods of treating a subject having an organ transplant for ACR are also provided. | 2012-01-19 |
20120014950 | Antibodies That Specifically Bind to DR3 - The present invention relates to antibodies, antibody fragments, and related molecules that specifically bind to DR3 receptors. Such antibodies have uses, for example, in the prevention, detection, diagnosis, treatment or amelioration of a disease or disorder, especially inflammatory and autoimmune diseases and other immune system disorders, such as Crohn's disease, colitis, Inflammatory Bowel Disease, arthritis, asthma, Multiple Sclerosis, atherosclerosis, and allergic disorders. The invention also relates to nucleic acid molecules encoding anti-DR3 receptor antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially inflammatory or autoimmune disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to DR3 receptor. | 2012-01-19 |
20120014951 | PCSK9 ANTAGONISTS - The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia. | 2012-01-19 |
20120014952 | COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS - Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system. | 2012-01-19 |
20120014953 | TREATING AND EVALUATING INFLAMMATORY DISORDERS - Methods of treating inflammatory disorders, such as rheumatoid arthritis, by modulating TWEAK and TNF-α are disclosed, as are other methods. | 2012-01-19 |
20120014954 | SPARC BINDING SCFVS - The invention provides compositions comprising SPARC binding ScFc and its use. | 2012-01-19 |
20120014955 | Antagonists of IL-6 to raise albumin and/or lower CRP - The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved. | 2012-01-19 |
20120014956 | METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-ALPHA INHIBITOR - The invention provides methods of determining or predicting the responsiveness of a subject to treatment with a TNFα inhibitor, such as a TNFα antibody by determining genetic factors. | 2012-01-19 |
20120014957 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 2012-01-19 |
20120014958 | STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF - The present invention relates to soluble and stable anti-VEGF immunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed. | 2012-01-19 |
20120014959 | WISE/SOST NUCLEIC ACID SEQUENCES AND AMINO ACID SEQUENCES - The present invention relates to nucleic acid sequences and amino acid sequences which influence bone deposition, the Wnt pathway, ocular development, tooth development, and may bind to LRP. The nucleic acid sequence and polypeptides include Wise and Sost as well as a family of molecules which express a cysteine knot polypeptide. Additionally, the present invention relates to various molecular tools derived from the nucleic acids and polypeptides including vectors, transfected host cells, monochronal antibodies, Fab fragments, and methods for impacting the pathways. | 2012-01-19 |
20120014960 | Composition Comprising Antibodies to LINGO or Fragments Thereof - Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody | 2012-01-19 |
20120014961 | ANTIBODIES THAT INHIBIT TSLP ACTIVITY - The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. | 2012-01-19 |
20120014962 | METHOD OF INHIBITING FIBROGENESIS AND TREATING FIBROTIC DISEASE - The present invention relates to the discovery of an epigenetic relay pathway that controls hepatic stellate cell activation and the wound-healing response in fibrogenesis, including fibrogenesis of the injured liver. Methods of inhibiting fibrogenesis, including liver fibrogenesis and secondary disease states and conditions thereof, and in treating liver damage, including cirrhosis of the liver (which may be caused by viruses or chemicals, including alcohol), are aspects of the present invention. The methods utilize certain nucleoside compounds and/or antibodies which are optionally conjugated. Pharmaceutical compositions represent additional aspects of the invention. | 2012-01-19 |
20120014963 | PROBIOTICS, SECRETORY IGA AND INFECTION - The present invention relates generally to the field of nutrition, health and wellness. In particular the present invention relates to probiotics and ways to increase their effectiveness. One embodiment of the present invention relates to a combination of probiotics with secretory IgA and possible uses of this combination. For example a use of a composition comprising secretory IgA and at least one probiotic for the preparation of a product to treat or prevent infection is disclosed. | 2012-01-19 |
20120014964 | ALPHA SYNUCLEIN TOXICITY - Present inventions demonstrates that alpha synuclein toxicity such as α-synuclein mediated cell death, alpha synuclein induced reactive oxygen species (ROS) in a cell requires the proapoptotic endonuclease G and that the deletion of the endonuclease G or suppressing of the endonuclease G apoptotic pathway attenuates or counteracts such alpha synuclein toxicity. The present invention compositions and methods for inhibition of α-synuclein toxicity. The inhibiting α-synuclein toxicity can be used in methods of treatment of synucleinopathies, such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), pure autonomic failure (PAF), and multiple system atrophy (MSA) and the manufacture of medicaments for such treatment. In particular The subject matter provided in herein relates to a pharmaceutical compositions containing inhibitors of endonuclease G, and their use in the treatment of synucleinopathies, such as Parkinson's disease, dementia with Lewy bodies, pure autonomic failure, and multiple system atrophy and the manufacture of medicaments for such treatment. Furthermore the present invention relates to a method for the identification of compounds attenuating the synuclein toxicity, said method comprising evaluating the inhibitory action of said compound on the endonuclease G dependent apoptosis. | 2012-01-19 |
20120014965 | COMPOSITIONS AND METHODS OF TREATING TUMORS - Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise administering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is deficient in tyrosine kinase activity. Composition that comprise such nucleic acid molecules including pharmaceutical compositions are disclosed. | 2012-01-19 |
20120014966 | METHODS FOR THE TREATMENT OF IL-1BETA RELATED CONDITIONS - Disclosed are methods and materials for inhibiting (e.g., treating or preventing) uveitis in a subject, including treatment refractory uveitis, using anti-IL-1β binding molecules (e.g., IL-1β binding antibodies or binding fragment thereof). | 2012-01-19 |
20120014967 | IL-1BETA BINDING ANTIBODIES AND FRAGMENTS THEREOF - An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency. | 2012-01-19 |
20120014968 | STABILIZED FORMULATIONS CONTAINING ANTI-NGF ANTIBODIES - The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human nerve growth factor (hNGF). The formulations may contain, in addition to an anti-hNGF antibody, at least one non-ionic surfactant, at least one sugar, and acetate. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months. | 2012-01-19 |
20120014969 | ErbB3 ANTIBODIES - Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3. | 2012-01-19 |
20120014970 | Therapeutic Compositions for Treatment of Corneal Disorders - The invention provides methods and compositions for minimizing, preventing, or treating damage to corneal nerves by administering to a subject with such damage or at risk of exposure to such damage a composition which blocks an activity of an IL-1 cytokine and/or an IL-17 cytokine. | 2012-01-19 |
20120014971 | Interleukin-1 Alpha Antibodies and Methods of Use - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors. | 2012-01-19 |
20120014972 | INFLUENZA VIRUS COMPOSITIONS AND METHODS FOR UNIVERSAL VACCINES - The disclosure relates at least in part to embodiments of compositions and methods including vaccines for protection against multiple serologically distinct strains of influenza virus. This disclosure provides significant advances and addresses important needs in the influenza vaccine field. | 2012-01-19 |
20120014973 | ADENYLYL CYCLASE-ASSOCIATED PROTEIN (CAP1) AND USES THEREOF AS A TARGET FOR IMMUNO-MODULATION - The present invention relates to the use of Adenylyl Cyclase-Associated Protein (CAP1) as a target for immuno-modulation. More specifically, the invention relates to the use of compounds that interact and bind CAP1, specifically, anti-CAP1 antibodies, and/or to CAP1 molecule or any fragments thereof, for the treatment of immune-related disorders by modulation of the Th1/Th2 balance. The invention further provides screening method for immuno-modulatory compounds that interact with CAP1. | 2012-01-19 |
20120014974 | METHODS OF MODULATING CELL DEATH BASED ON THE BIT1/AES REGULATORY PATHWAY - The present invention provides a method of identifying an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. The method is practiced by contacting a Bit1 polypeptide, or active fragment thereof, and an AES polypeptide, or active fragment thereof, with an agent under conditions that allow the Bit1 polypeptide or active fragment thereof to associate with the AES polypeptide or active fragment thereof; and detecting an altered association of the Bit1 polypeptide or active fragment thereof and the AES polypeptide or active fragment thereof, where an altered association indicates that the agent is an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. Such an effective agent can modulate apoptosis and can be a useful therapeutic agent. | 2012-01-19 |
20120014975 | MODIFIED SINGLE DOMAIN ANTIGEN BINDING MOLECULES AND USES THEREOF - The invention relates to modified single domain antigen binding molecules, e.g., SDAB molecules, in particular TNFα-binding SDAB molecules. Method of preparing, and using the modified single domain antigen binding molecules described herein, to treat, e.g., TNFα-associated disorders, are also disclosed. | 2012-01-19 |
20120014976 | COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE RESPONSES TO VACCINES - The disclosure provides adjuvants, immunogenic compositions, and methods useful for vaccination and immune response. In particular, the disclosure provides a class of adjuvants comprising cationic lipid:co-lipid mixtures and methods for delivering formulated compositions. | 2012-01-19 |
20120014977 | NOVEL ALTERNATIVE SPLICING VARIANT OF OATP1B3 mRNA - [PROBLEM TO BE SOLVED] An object of the present invention is to provide a novel tumor marker and use thereof. In more detail, the present invention provides a novel tumor marker, a method for measuring said tumor marker and a measurement kit, a method for detecting cancer using the same, a kit for detecting cancer, a method for screening a preventive and/or therapeutic agent for cancer, as well as a medicament such as cancer vaccine. | 2012-01-19 |
20120014978 | COMPOSITIONS WITH REDUCED DIMER FORMATION - The present invention relates to the use of a non-reducing carbohydrate or carbohydrate derivative and at least one agent which inhibits dimer formation in a freeze-dried composition comprising at least one peptide that contains a free cysteine residue, to provide a freeze-dried composition with improved long-term storage stability. | 2012-01-19 |
20120014979 | USE OF BCL6 INHIBITORS FOR TREATING AUTOIMMUNE DISEASES - The present invention provides a method of treatment of an autoimmune disease, comprising administering an effective amount of a BCL6 inhibitor to an individual in need thereof. | 2012-01-19 |
20120014980 | VACCINES COMPRISING TB10.4 - Vaccination with the combination of Ag85B-TB10.4 and IC31® adjuvant generated a high amount of polyfunctional CD4 | 2012-01-19 |
20120014981 | AVIRULENT, IMMUNOGENIC FLAVIVIRUS CHIMERAS - Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses. | 2012-01-19 |
20120014982 | Methods and Compositions for Immunizing Against Chlamydia Infection - The present invention relates, in part, to methods and compositions for immunizing against infection by | 2012-01-19 |
20120014983 | RECOMBINANT ALPHA-HEMOLYSIN POLYPEPTIDE OF STAPHYLOCOCCUS AUREUS, HAVING A DELETION IN THE STEM DOMAIN AND HETEROLOGOUS SEQUENCES INSERTED - It refers to a recombinant alpha-hemolysin polypeptide of | 2012-01-19 |
20120014984 | COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS - This invention provides compositions and methods for treating and vaccinating against an Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a non-human animal. | 2012-01-19 |
20120014985 | Vaccine Adjuvants - The invention relates to a novel adjuvant | 2012-01-19 |
20120014986 | COMPOSITIONS AND METHODS FOR REDUCING INFLAMMATION - Blue-green algae, such as | 2012-01-19 |
20120014987 | DNA VACCINE FOR ALZHEIMER'S DISEASE - The present invention aims to provide a DNA vaccine for Alzheimer's disease. | 2012-01-19 |
20120014988 | REPLICATION DEFICIENT RECOMBINANT VIRUSES EXPRESSING ANTIGENS REGULATED BY TRANSCRIPTIONAL CONTROL ELEMENTS COMPRISING MULTIPLE ELEMENTS - The present invention relates to a replication deficient recombinant virus encoding at least one antigen and/or antigenic epitope, wherein expression of said antigen and/or antigenic epitope is regulated by a transcriptional control element comprising at least two elements driving early expression of said antigen and/or antigenic epitope and the use of said replication deficient recombinant virus as medicament or vaccine. | 2012-01-19 |
20120014989 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS - The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer. | 2012-01-19 |
20120014990 | VACCINATION METHODS - In one aspect, a method of treating cancer in a mammal is provided. The method comprises administering to the mammal an oncolytic vector that expresses a tumour antigen to which the mammal has a pre-existing immunity. In another aspect, a method of boosting immune response in a mammal having a pre-existing immunity to an antigen is provided comprising intravenous administration to the mammal of a B-cell infecting vector that expresses the antigen. | 2012-01-19 |
20120014991 | NOVEL, NON-ANTIGENIC, MUCOSAL ADJUVANT FORMULATION WHICH MODULATES THE EFFECTS OF SUBSTANCES, INCLUDING VACCINE ANTIGENS, IN CONTACT WITH MUCOSAL BODY SURFACES - Adjuvant for mucosal vaccines which modulates the effects of substances, including vaccine antigens in contact with mucosal body surfaces. | 2012-01-19 |
20120014992 | N-Linked Glycosylation Alteration in E1 Glycoprotein of Classical Swine Fever Virus And Novel Classical Swine Fever Virus Vaccine - E1, along with Erns and E2 is one of the three envelope glycoproteins of Classical Swine Fever Virus (CSFV). Our previous studies indicated that glycosylation status of either E2 or Erns strongly influence viral virulence in swine. Here, we have investigated the role of E1 glycosylation of highly virulent CSFV strain Brescia during infection in the natural host. The three putative glycosylation sites in E1 were modified by site directed mutagenesis of a CSFV Brescia infectious clone (BICv). A panel of virus mutants was obtained and used to investigate whether the removal of putative glycosylation sites in the E1 glycoprotein would affect viral virulence/pathogenesis in swine. We observed that rescue of viable virus was completely impaired by removal of all three putative glycosylation sites in E1. Single mutations of each of the E1 glycosylation sites showed that CSFV amino acid N594 (E1.N3 virus), as well the combined mutation of N500 and N513 (E1.N1N2 virus) resulted in BICv attenuation. Infection of either E1.N1N2 or E1.N3 viruses were able to efficiently protected swine from challenge with virulent BICv at 3 and 28 days post-infection. These results, along with those demonstrating the role of glycosylation of E | 2012-01-19 |
20120014993 | CLOSTRIDIUM TAENIOSPORUM SPORES AND SPORE APPENDAGES AS SURFACE DISPLAY HOSTS, DRUG DELIVERY DEVICES, AND NANOBIOTECHNOLOGICAL STRUCTURES - The present disclosure relates to spore surface display compositions comprising a spore having at least one nucleic acid sequence encoding for at least one polypeptide and operable to express the polypeptide on a surface of the spore. In some embodiments, the displayed polypeptide is displayed with a spore carrier protein. In some embodiments, the spore may be derived from a | 2012-01-19 |
20120014994 | Malaria prime/boost vaccines - Described are vaccine regimens in which specific prime/boost regimens are applied using low-neutralized recombinant adenoviral vectors harboring nucleic acids encoding antigens from | 2012-01-19 |
20120014995 | PHARMACEUTICAL COMPOSITIONS AND METHODS TO VACCINATE AGAINST DISSEMINATED CANDIDIASIS AND OTHER INFECTIOUS AGENTS - The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of | 2012-01-19 |
20120014996 | METHOD OF DIAGNOSING BLADDER CANCER - Objective methods for detecting and diagnosing bladder cancer (BLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BLC-associated gene that discriminates between BLC cells and normal cells. The present invention further provides means for predicting and preventing bladder cancer metastasis using BLC-associated genes having unique altered expression patterns in bladder cancer cells with lymph-node metastasis. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of bladder cancer, methods of treating bladder cancer and method for vaccinating a subject against bladder cancer. In particular, the present application provides novel human genes C2093, B5860Ns and C6055s whose expression is markedly elevated in bladder cancers. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of bladder cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of bladder cancer. | 2012-01-19 |
20120014997 | ARYL SULFONAMIDES - Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists. | 2012-01-19 |
20120014998 | MODIFIED CHAPERONIN 10 - The present invention relates to isolated Chaperonin 10 polypeptides possessing immunomodulatory activity, but lacking, or substantially lacking, protein folding activity. | 2012-01-19 |
20120014999 | Diketopiperazine Microparticles with Defined Specific Surface Areas - Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m | 2012-01-19 |
20120015000 | MALARIA VACCINE OF SELF-ASSEMBLING POLYPEPTIDE NANOPARTICLES - The invention is directed to functionalized self-assembling polypeptide nanoparticles, and to methods of using these nanoparticles to vaccinate against malaria. The functionalized SAPN comprises a self-assembling core, and at least one epitope fused to the self-assembling core. The self-assembling core comprises a pentameric coiled-coil domain, a trimeric coiled-coil domain, and a linker. The linker joins the pentameric coiled-coil domain and the trimeric coiled-coil domain. Particular sequences of the epitopes used in the vaccine are from the | 2012-01-19 |
20120015001 | METHODS OF TREATING THYROID EYE DISEASE - The present invention relates to a methods and compositions for the treatment of and management of symptoms for thyroid eye disease. The methods include administering to a patient having thyroid eye disease an agent that interferes with hyaluronan synthesis in an amount that is effective to inhibit hyaluronan synthesis in a retro-ocular space. The pharmaceutical compositions hat includes a carrier suitable for ophthalmic delivery and an agent that interferes with hyaluronan synthesis. Combination therapies are also disclosed. | 2012-01-19 |
20120015002 | ANTIMICROBIAL COATINGS - The disclosure provides polymers having antimicrobial activity and articles with the polymers coated thereon. The polymers include a first pendant group comprising a first quaternary ammonium component, a second pendant group comprising a nonpolar component, and a third pendant group comprising an organosilane component. The disclosure also includes methods of coating articles with the antimicrobial polymers. The methods further include the use of adhesion-promoting reagents. | 2012-01-19 |
20120015003 | Layered Scaffold Suitable for Osteochondral Repair - The invention relates to a method for producing a multi-layer collagen scaffold. The method generally comprises the steps of: preparing a first suspension of collagen and freezing or lyophilising the suspension to provide a first layer; optionally preparing a further suspension of collagen and adding the further suspension onto the layer formed in the previous step to form a further layer, and freezing or lyophilising the layers, wherein when the layer formed in the previous step is formed by lyophilisation the lyophilised layer is re-hydrated prior to addition of the next layer; optionally, repeating the aforementioned step to form one or more further layers; and preparing a final suspension of collagen and pouring the final suspension onto the uppermost layer to form a final layer, and freeze-drying the layers to form the multilayer collagen composite scaffold. | 2012-01-19 |
20120015004 | ENCAPSULATED SALTS AND USE IN HIGH ACID BEVERAGES - Encapsulated nutrient salts including nutrient salt particles encapsulated with a water-insoluble chitosan-stearic acid complex are provided. A method for forming encapsulated nutrient salts is provided, including forming a water-in-oil micro-emulsion including an oil and an aqueous salt solution, adding chitosan and stearic acid to the water-in-oil micro-emulsion, where the chitosan and stearic acid form a complex, and collapsing the aqueous phase of the water-in-oil micro-emulsion to form the encapsulated salt particles. | 2012-01-19 |
20120015005 | METHODS OF TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) USING CYSTEAMINE PRODUCTS - The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). | 2012-01-19 |
20120015006 | FLOWABLE COLLAGEN MATERIAL FOR DURAL CLOSURE - Flowable graft materials are provided which comprise collagen powder and a liquid in an amount sufficient to impart a flowable consistency to the material. The graft materials are sufficiently formable and pliable so as to provide both superior contact with and easier access to a surgical site than typical, more rigid grafts such as collagen sheets. These flowable materials may also be in a fluidized, paste-like and/or gel-like state and may be moldable and/or ejectable. The flowable collagen materials reduce and/or eliminate post implantation problems associated with other materials, e.g. synthetic dural sealants (hemostasis products), such as product swelling after application and implantation. The flowable graft materials are particularly useful as a dural graft. | 2012-01-19 |
20120015008 | ANTI-ADHESIVE COMPOSITION, SOLID PREPARATION, AND PROCESS FOR PRODUCING THE SAME - An adhesion of a preparation | 2012-01-19 |
20120015009 | Multi-phased personal care composition comprising a blooming perfume composition - A multi-phase personal care composition is described comprising is a first phase and a second phase. The personal care composition comprises at least 0.25%, by weight of the composition, of blooming perfume ingredients having a KI of less than about 1500. | 2012-01-19 |
20120015010 | Compositions Comprising Pigment Particles Entrapped In Collapsed Polymeric Microspheres, And Methods Of Making The Same - Topical compositions containing pigment particles entrapped in microspheres are provided. Each of the microspheres contains a collapsed polymeric shell that has entrapped therein one or more pigment particles. The microsphere-entrapped pigment particles are characterized by enhanced color intensity, improved stability, and better dispersibility, which can readily be used either alone or in combination with other skin active ingredients to form better colored cosmetics. | 2012-01-19 |
20120015011 | COSMETIC COMPOSITION COMPRISING DOUBLE-SHELL NANO-STRUCTURE - Disclosed is a cosmetic composition having a double-shell type nano-structure. More particularly, the nano-structure of the cosmetic composition includes: a water-soluble bioactive ingredient core; a core shell containing poly(ethyleneglycol)-poly(caprolactone)-poly(ethyleneglycol) (PE-PCL-PEG) triblock copolymer in order to include the bioactive ingredient core therein; and an outer shell containing phospholipids or derivatives thereof in order to enclose the core shell therein. Such a cosmetic composition improves stability of active components which are prone to oxidation, light degradation, heat degradation, etc., is formed in a nanoparticle size which in turn shows high transdermal absorption and is very useful to prepare a cosmetic composition stably encapsulating various bioactive ingredients with anti-wrinkle effects, whitening effects, and so forth. | 2012-01-19 |
20120015012 | COSMETIC COMPOSITION CONTAINING KETOGLUCONIC ACID DERIVATIVES - Cosmetic compositions containing at least one derivative of ketogluconic acid and use thereof as anti-ageing and skin restructuring agent. | 2012-01-19 |
20120015013 | MATRIX CONTAINING METAL OXIDE PARTICLES AND USE OF SAME IN COSMETIC COMPOSITIONS - A macroparticle sunscreen powder and methods of making the same. The macroparticle sunscreen powder includes a plurality of macroparticle particles that include UV attenuating particles in a matrix material selected from the group consisting of a natural latex, polyacrylate, polymethacrylate, polyurethane, polyvinyl acetate, styrene-butadiene rubber, acrylonitrile butadiene styrene copolymer, and combinations thereof. | 2012-01-19 |
20120015014 | COMPOSITION EXHIBITING ENHANCED FORMULATION STABILITY AND DELIVERY OF TOPICAL ACTIVE INGREDIENTS - A therapeutic, cosmetic or cosmeceutic composition for topical application, capable of stabilizing an active ingredient and delivering the active ingredient, comprising a plurality of microcapsules having a core-shell structure. The microcapsules have a diameter of approximately 0.1 to 100 micron. The core of each microcapsule includes at least one active ingredient, and is encapsulated within a microcapsular shell. The shell is comprised of at least one inorganic polymer obtained by a sol-gel process, and the shell protects the active ingredient before topical application and is designed to release the active ingredient from the microcapsules following application. The composition is useful in encapsulating active ingredients, such as benzoyl peroxide, that are unstable in other formulation, or are irritating to the skin. | 2012-01-19 |
20120015015 | COMPOSITE POWDER FOR SIMULTANEOUSLY BLOCKING INFRARED AND ULTRAVIOLET RAYS AND COSMETICS COMPOSITION USING THE SAME - Disclosed is composite powder comprising infrared-ray blocking particles; and ultraviolet-ray blocking particles coated onto one surface of each of the infrared-ray blocking particles, and cosmetics composition using the same, wherein the composite powder using both the infrared-ray blocking particle and the ultraviolet-ray blocking particle enables to simultaneously block the infrared and ultraviolet rays. Thus, if the composite powder of the present invention is applied to the cosmetics, it is possible to minimize the rough wrinkles, irregular pigmentary deposits, loss of skin elasticity, disturbance of skin barrier function, skin damages such as cancer of the skin, and skin aging, and also to boost SPF (Sun Protection Factor) and PA (Protection Factor of UVA) of the related art sunscreen. Especially, the present invention uses the composite powder prepared by coating one surface of the infrared-ray blocking particle with the ultraviolet-ray blocking particles, instead of mixing powder prepared by simply mixing the infrared-ray blocking particle and the ultraviolet-ray blocking particle. That is, since the small-sized ultraviolet-ray blocking particles are coated onto and stably fixed into the surface of the infrared-ray blocking particle, it is possible to prevent aggregation of the ultraviolet-ray blocking particles, thereby preventing deterioration in uniformity of adhesion to the skin, and deterioration of the ultraviolet-ray blocking efficiency. | 2012-01-19 |
20120015016 | UV Protecting Composition And Methods Of Use - The present application relates to a UV protecting composition containing: (a) at least one organic UV sunscreen active; (b) at least one semi-crystalline polymer which is solid at ambient temperature and has a melting point of less than about 8O0 C; (c) hollow latex particles; and (d) at least one additional ingredient chosen from: i) a UV light absorbing compound having an SPF of less than 2, and ii) an SPF booster capable of reflecting UV light, different from hollow latex particles, wherein the hollow latex particles are employed in an amount equal to, or greater than, the amount of the at least one organic UV sunscreen active present in the composition. The invention also relates processes for protecting cellular targets from UV rays and free radical-induced damage by topically applying a UV protecting composition onto a keratinous substance, such as skin, and processes for making such compositions. | 2012-01-19 |
20120015017 | Slow releasing microcapsules containing an active substance - A production method is provided for the preparation of small polymer microcapsules with an oil core and solid microspheres, containing high amounts of biocide by internal phase separation from emulsion droplets with ethyl acetate as a solvent. The size of the microcapsules and microspheres can be controlled with a high degree of accuracy between 0.2-20 micrometers in diameter. The microparticles are particularly well suited for coatings such as paints, lacquers and wood preservatives which are to be protected against microorganisms using biocides, as well as for surface protection directly, i.e. without combining the microparticles with a coating material. | 2012-01-19 |
20120015018 | Mixed antibacterial glass - There is provided a mixed antibacterial glass which stably controls the silver ion elution amount from the antibacterial glass into the drain water in an air conditioning system, thereby effectively preventing the occurrence of microorganisms in the drain water. | 2012-01-19 |
20120015019 | Drug Coated Balloon With In-Situ Formed Drug Containing Microspheres - The current invention relates to methods of forming a coating that involves the in-situ formation of drug microspheres. The coating may be applied to a medical device, such as a catheter balloon or a stent. Coated devices and methods of treatment therewith are also encompassed within the embodiments of the present invention. | 2012-01-19 |
20120015020 | BIODEGRADABLE DRUG OR OTHER ACTIVE DELIVERY SYSTEM - A nonwoven fabric has been developed as a delivery system for drugs or other actives which includes biodegradable and biocompatible fibers with plant virus nanoparticles. The plant virus nanoparticles are pre-loaded with one or more actives. | 2012-01-19 |
20120015021 | ANTI-APPETITE ADHESIVE COMPOSITIONS - Compositions for appetite suppression and methods of making and using thereof are disclosed herein. The compositions are typically in the form of a tablet, such as a single or multi-layer sticker tablet. The compositions adhere to a buccal surface or mucosal surface in the oral cavity for at least 15 minutes, preferably for at least 30 minutes. In a preferred embodiment, the compositions contain herbal agents that are anti-appetite agents. The composition is generally effective for suppressing appetite for a time period ranging from at least 30 minutes up to eight hours following administration to the buccal or oral mucosa. | 2012-01-19 |
20120015022 | Biodegradable wound care products with biocompatible artificial skin treatment - A biodegradable wound care product with biocompatible artificial skin treatment is described. It includes a biodegradable bandage support member and a biodegradable adhesive on at least a portion thereof. The support member is made of a biodegradable material, such as natural or artificial textiles, plastics or papers. The biodegradable actives carrier is attached to a portion of the biodegradable bandage support member and is a synthetic or natural biodegradable adhesive or a combination thereof. The active ingredient located on the biodegradable actives carrier includes a layer of biocompatible algae artificial skin including sterilized water and at least sixty percent by weight of reconstituted seaweed. Laminaria seaweed may be used for its desirable polyfucose sulfate content. The active ingredient is prepared by first drying the raw materials, converting the raw materials to a powder and then reconstituting the powder with sterilizes water and other possible actives and/or inerts. | 2012-01-19 |
20120015023 | Treatment of tumors prostate with arsonoliposomes - The invention provides a method for treating a prostate proliferative disorder, such a prostate carcinoma or a begnin prostatic hyperplasia, in a patient, which method comprises administering arsonoliposomes comprising arsonolipids, wherein the arsonolipids are 2,3-diacyloxypropylarsonic acids, to a patient in need thereof. | 2012-01-19 |
20120015024 | METHODS FOR TREATING TWEAK-RELATED CONDITIONS - The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists. | 2012-01-19 |
20120015025 | CHOLESTANOL DERIVATIVE FOR COMBINED USE - The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. | 2012-01-19 |
20120015026 | PHARMACEUTICAL COMPOSITION CONTAINING A DRUG AND SIRNA - The present invention relates generally to the fields of molecular biology, medicine, oncology, and delivery of therapeutic compounds. In particular, the present invention relates to pharmaceutical compositions containing a hydrophobic drug substance and an inhibitory nucleic acid molecule, such as short interfering RNA (siRNA), in a single drug delivery system, as well as a process for making and a process for administering the same. | 2012-01-19 |
20120015027 | F, G, H, I and K Crystal Forms of Imatinib Mesylate - The invention relates to the F-crystal form, G-crystal form, H-crystal form, I-crystal form and K-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-( | 2012-01-19 |
20120015028 | Controlled-Released Osmotic Pump Tablet with Lubricating Layer and the Preparation Thereof - An osmotic pump in form of controlled release tablet and the preparation thereof are disclosed Said tablet includes a double-layer tablet core consisted of a drug layer ( | 2012-01-19 |
20120015029 | DIRECT COMPRESSION FORMULATION AND PROCESS - This invention relates to tablets especially tablets formed by direct compression of a dipeptidylpeptidase IV (DPP-IV) inhibitor compound, a process for the preparation thereof, to new pharmaceutical formulations, and new tableting powders comprising DPP-IV inhibitor formulations capable of being directly compressed into tablets. The invention relates further to a process for preparing the tablets by blending the active ingredient and specific excipients into the new formulations and then directly compressing the formulations into the direct compression tablets. The invention also relates to vildagliptin particle size distribution and a new crystal form of vildagliptin particularly adapted for the preparation of improved tablets and other pharmaceutical compositions. | 2012-01-19 |
20120015030 | MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES - A solid dose composition containing a mixture of a cured, modified release-barrier coated methylphenidate-ion exchange resin complex-matrix and an uncoated methylphenidate-ion exchange resin complex is described. The barrier coated methylphenidate-ion exchange resin complex-matrix comprises methylphenidate complexed with a pharmaceutically acceptable ion-exchange resin to form the complex which is admixed with a polymer to form a methylphenidate-ion exchange resin complex-matrix, which is subsequently coated with a modified release coating. The modified coating contains polyvinyl acetate polymer and a plasticizer and is cured. | 2012-01-19 |
20120015032 | COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME - The present invention relates to a chronotherapeutically combined pharmaceutical formulation for preventing and treating cardiovascular diseases, which is based on the principle of administering a plurality of drugs at certain time intervals (chronotherapy). Specifically, the combined pharmaceutical formulation comprises a HMG-CoA reductase inhibitor, such as simvastatin, and aspirin. Because the combined pharmaceutical formulation was developed based on the principle of administering drugs at certain time intervals, so-called chronotherapy, it shows an excellent effect of preventing or treating cardiovascular disease compared to those of the individual administration and simultaneous administration of the single preparations. Also, it is a once-daily dosage form which increases the medication compliance of patients. Particularly, even though the content of aspirin in the combined pharmaceutical formulation is reduced, the platelet aggregation inhibitory effect of aspirin in the combined pharmaceutical formulation is equal to that of the amount of aspirin used in the prior art, while the aspirin in the combined pharmaceutical formulation shows a antihypertensive effect. In addition, the chronotherapeutically combined pharmaceutical formulation allows the two drugs, which interact with each other, to be stored for a long period of time, and the combined pharmaceutical formulation ensures the human body-safety and efficacy of the two drugs. | 2012-01-19 |
20120015033 | ANTISENSE COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease. | 2012-01-19 |